Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

26.86 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Viking Therapeutics Q3 Earnings Call Highlights ↗

October 29, 2026

Viking Therapeutics (NASDAQ:VKTX) reported a wider third-quarter loss as it increased spending on late-stage obesity programs, while advancing phase III studies of both injectable and oral versions of...

Via MarketBeat

Topics Earnings

Viking (VKTX) Q3 2026 Earnings Call Transcript ↗

October 29, 2026

VK2735 obesity drug shows up to 22% weight loss with less frequent dosing schedules.

Via The Motley Fool

Topics Earnings

Viking Therapeutics (NASDAQ:VKTX) Q3 2026 Earnings: Wider Loss as Obesity Pipeline Advances ↗

October 28, 2026

Via Chartmill

Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 Years ↗

October 20, 2026

Viking Therapeutics has a lot riding on its leading pipeline candidate.

Via The Motley Fool

Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2 ↗

October 20, 2026

Nothing is certain in clinical trials, but investors have reason to expect a better outcome in the oral VK2735 trials.

Via The Motley Fool

Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter. ↗

October 18, 2026

Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735.

Via The Motley Fool

4 High-Risk Stocks Built for Big Returns ↗

October 14, 2026

These speculative investments could turbocharge a portfolio to market-beating returns.

Via The Motley Fool

Topics Artificial Intelligence

3 Absurdly Cheap Stocks to Buy Before the End of 2026 ↗

October 13, 2026

These stocks are priced incredibly low and possess significant upside.

Via The Motley Fool

Oppenheimer Thinks Viking Therapeutics Stock Can Soar to $120. Here's the Math Behind the Ultra-Bullish Call. ↗

October 12, 2026

Oppenheimer raised Viking Therapeutics' price target to $120, citing strong trial data, and an improving probability of success for its key drug.

Via The Motley Fool

2 Stocks That Could Soar in Q4 ↗

October 12, 2026

These growth companies offer investors the potential for near-term upside from fourth-quarter catalysts and long-term growth from realizing value in their pipelines.

Via The Motley Fool

Viking Therapeutics' Oral Obesity Drug Advances to Phase 3 Testing. Is Now the Time to Buy This Biotech Stock? ↗

October 10, 2026

Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.

Via The Motley Fool

Here Are My Top 4 Stocks to Buy in October ↗

October 05, 2026

Get 'em while they're still on sale. Catalysts are on the horizon.

Via The Motley Fool

Topics Artificial Intelligence

Should You Buy Viking Therapeutics Stock While It Trades Below Its $35 Offering Price? ↗

October 02, 2026

The weight loss drug company continues to make progress, but its share price is bouncing around with events.

Via The Motley Fool

Prediction: This Stock Could Double Over the Next 5 Years ↗

October 02, 2026

The obesity drug market is so large that only a small market share could lead to substantive price appreciation for the stock.

Via The Motley Fool

Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy ↗

September 30, 2026

Could this be what Novo needs to turn things around?

Via The Motley Fool

Topics Initial Public Offering

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock. ↗

September 30, 2026

There could be more catalysts for the biotech over the next 18 months.

Via The Motley Fool

3 Emerging Biotech Stocks With Significant Upside Potential ↗

September 30, 2026

Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.

Via MarketBeat

Topics Intellectual Property

Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. ↗

September 29, 2026

Both stocks may be worth considering for those looking to capitalize on the anti-obesity market.

Via The Motley Fool

3 Non-AI Growth Stocks That Have Massive Upside ↗

September 29, 2026

Investors looking for some compelling growth opportunities outside of tech may want to consider these stocks.

Via The Motley Fool

Topics Artificial Intelligence

Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly? ↗

September 28, 2026

Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.

Via The Motley Fool

Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution ↗

September 27, 2026

The company recently delivered some exciting trial data, but it also needs to deliver in the second part of the trial.

Via The Motley Fool

3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing ↗

September 27, 2026

The company continues to make good progress with its key obesity treatment drug, VK2735.

Via The Motley Fool

MarketBeat Week in Review – 09/21 - 09/25 ↗

September 26, 2026

A weekly roundup of MarketBeat analysis on volatile markets, oil, bond rates, AI stocks, dividend picks, and earnings outlooks, covering companies from NVIDIA to Tesla and Qualcomm.

Via MarketBeat

Topics Artificial Intelligence Bonds Economy

Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? ↗

September 25, 2026

The biotech player could eventually rival big pharma companies.

Via The Motley Fool

Here's Why Viking Therapeutics Shares Slumped Today ↗

September 24, 2026

It's been an eventful week for the weight-loss drug company, which continues to impress with its clinical data, and today's move isn't much to worry about.

Via The Motley Fool

Viking's Obesity Edge May Be Staying Power, Not Weight Loss ↗

September 23, 2026

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

Via MarketBeat

Why Viking Therapeutics Stock Skyrocketed on Tuesday ↗

September 23, 2026

The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off.

Via The Motley Fool

Which stocks are experiencing notable movement on Tuesday? ↗

September 22, 2026

Via Chartmill

What's going on in today's session ↗

September 22, 2026

Via Chartmill

Gapping stocks in Tuesday's session ↗

September 22, 2026

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.